Singapore#s IP Office to Grant Merck#s Patent Application for CRISPR Technology

Food and Healthcare Press Releases Wednesday December 20, 2017 08:05
DARMSTADT, Germany--20 Dec--PRNewswire/InfoQuest
  • Patent covers successful integration of an external DNA sequence into the chromosome of eukaryotic cells using CRISPR
  • Fourth patent allowance for Merck's CRISPR technology; similar patents from Australian, Canadian and European Patent Offices already received
  • Merck to license its CRISPR-related patents to interested parties

Merck , a leading science and technology company, today announced that the Intellectual Property Office of Singapore has issued a "Notice of Eligibility for Grant" for Merck's patent application covering the company's CRISPR technology used in a genomic-integration method for eukaryotic cells.

Photo - http://mma.prnewswire.com/media/620848/Merck.jpg

"Singapore's notice of patent allowance for Merck's CRISPR integration technology is yet another reinforcement of our intellectual property," said Udit Batra, Member of the Merck Executive Board and CEO, Life Science. "We look forward to receiving additional grants for similar patent applications in several other countries as we collaborate with the global scientific community to find new treatments for diseases."

Merck is now licensing these foundational integration patent allowances for applications including basic science research, agricultural biotech and therapeutic use.

This forthcoming, fundamental patent in Singapore, entitled "CRISPR-BASED GENOME MODIFICATION AND REGULATION," covers chromosomal integration, or cutting of the chromosomal sequence of eukaryotic cells (such as mammalian and plant cells) and insertion of an external or donor DNA sequence into those cells using CRISPR. Scientists can replace a disease-associated mutation with a beneficial or functional sequence, a method important for creating disease models and gene therapy. Additionally, the method can be used to insert transgenes that label endogenous proteins for visual tracking within cells.

CRISPR genome-editing technology, which allows the precise modification of chromosomes in living cells, is advancing treatment options for some of the toughest medical conditions faced today. CRISPR applications are far-ranging —from identifying genes associated with cancer and rare diseases to reversing mutations that cause blindness.

Once issued, the Singapore patent will extend the protection of Merck's CRISPR integration technology into Singapore, further strengthening the company's patent portfolio. Merck also has patent filings for its insertion CRISPR method in the U.S., Brazil, China, India, Israel, Japan and South Korea. In June 2017, Merck was awarded its first CRISPR patent by the Australian patent office. That award was followed by related patent awards by European and Canadian Patent Offices.

With a 12-year history in the genome-editing field, Merck was the first company to offer custom biomolecules for genome editing globally (TargeTron(TM) RNA-guided group II introns and CompoZr(TM) zinc finger nucleases), driving adoption of these techniques by researchers all over the world. Merck was also the first company to manufacture arrayed CRISPR libraries covering the entire human genome, accelerating cures for diseases by allowing scientists to explore more questions about root causes.

Merck recognizes the potential benefits of conducting properly defined research with genome editing because of the breakthrough therapeutic potential. Therefore, Merck supports research with genome editing under careful consideration of ethical and legal standards. Merck has established a Bioethics Advisory Panel to provide guidance for research in which its businesses are involved, including research on or using genome editing.

All Merck news releases are distributed by email at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

About Merck

Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck generated sales of EUR15 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck holds the global rights to the "Merck" name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.


Latest Press Release

Experts Discuss Decentralized Manufacturing to Tackle Neglected Tropical Diseases and Promote Universal Health Coverage at World Health Assembly Event

- Global health leaders covered biomanufacturing and neglected tropical diseases (NTDs) during 72nd World Health Assembly - Event focused on innovative science and technology-based solutions to increase access to medicines and biologics Merck, a...

Menarini Ricerche at the ASCO Annual Meeting 2019 With Three Different Projects in Oncology

Menarini Ricerche will present three different projects related to the compounds in clinical development SEL24/MEN1703, MEN1611 and MEN1309/OBT076 at the ASCO Annual Meeting 2019 in Chicago. During the poster session "Breast Cancer – Metastatic"...

Surgical Specialties Corporation Launches Caliber Ophthalmics Division to Focus on Global Growth of Ophthalmic Surgical Procedures

Surgical Specialties Corporation (SSC) announced today the launch of Caliber Ophthalmics, a new business division. Caliber Ophthalmics combines SSC's Sharpoint(TM) brand, which has earned a trusted reputation serving ophthalmic surgeons for over 50...

After $7.1 Billion Sale Of Frutarom, Ori Yehudai To Join The Sade Group As Active Chairman and Investor

Ori Yehudai: "I took a company worth $3 million and sold it to IFF at $7.1 billion in 2018. In my opinion, the success of our cannabis company will be to build an industrial pharmaceutical company with the strictest standards, we had two such plants, and...

A New Approach to Treating Alzheimer#s Disease Receives Major NIA Backing

T3D Therapeutics to Receive $9 Million Multiyear National Institute on Aging Grant for Phase 2 PIONEER Study in Mild-to-Moderate Alzheimer's Disease Patients T3D Therapeutics, a clinical stage drug development company engaged in the development of...

Related Topics